Support group hears about new treatments

Support group hears about new treatments

The Parkinson’s Disease Support Group April meeting at the McGee Center celebrated spring with decorations and activities to highlight the season. Attendees also shared information about recent research into the causes and treatments of Parkinson’s disease.

1ST Biotherapeutics joins MJFF LRRK2 gene-targeting program

1ST Biotherapeutics said it joined an initiative led by the Michael J. Fox Foundation (MJFF) aimed at advancing therapies that target the LRRK2 gene, a key genetic contributor to Parkinson’s disease. The initiative, MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program, brings together biotech companies and academic research institutions with the shared goal of developing LRRK2-targeting treatments for Parkinson’s. Collaborators in the…

Stem-cell therapy for Parkinson's shows 'strong promise' in relieving symptoms - Daily news Update

With around one million people living with Parkinson’s disease in the U.S. — and 90,000 getting new diagnoses each year — the race is on for a cure. Researchers at Memorial Sloan Kettering Cancer Center (MSK) have announced progress on that front — they have developed a new therapy that uses stem cells to treat advanced Parkinson’s. In the phase 1 trial, the researchers used donated stem cells (taken from early-stage embryos) to create nerve cel…

Do we witness a revolution in the management of patients with Parkinson's disease? Two teams of researchers have succeeded in grafting neurons that secrete dopamine into the brains of patients. The lighting of Dr. Vincent Valinducq in "Hello! Morning TF1". - The transplant of neurons, a hope for patients with Parkinson's disease (Health and well-being).